GlassScriptPhysician profile
Farideddin Nossoni
NPI 1699189456
$6,058.23
in general payments reported to CMS, 2019-2025
23 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $1,619 · 2021: $1,038 · 2022: $1,279 · 2023: $289 · 2024: $605 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $1,000.38 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Mentor Worldwide LLC | $964.83 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Integra Lifesciences Corporation | $761.84 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Allergan, INC. | $710.51 | 2019-2022 | |
| Axogen | $577.58 | 2019-2020 | |
| Medical Device Business Services, INC. | $559.98 | 2020-2021 | |
| Kerecis Limited | $352.71 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Ethicon US, LLC | $212.44 | 2019-2022 | |
| Depuy Synthes Sales INC. | $210.42 | 2020-2025 | Trumatch |
| Baxter Healthcare | $125.59 | 2021 | |
| Medela LLC | $119.61 | 2020 | |
| Acell, INC. | $112.74 | 2019 | |
| Acera Surgical, INC. | $104.16 | 2025 | Restrata Wound Matrix |
| Sientra, INC. | $39.39 | 2022 | |
| Davol INC. | $35.50 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $27.72 | 2020 | |
| Smith+Nephew, INC. | $24.97 | 2021 | |
| Pinnacle, INC | $23.55 | 2021 | |
| Abbvie INC. | $23.38 | 2025 | |
| Bioventus LLC | $23.10 | 2022 | |
| Motiva USA, LLC | $17.46 | 2025 | |
| Coopersurgical, INC. | $16.50 | 2025 | Insorb |
| Pacira Pharmaceuticals Incorporated | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farideddin Nossoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.